| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | For the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 (tumour proportion score [TPS] ≥ 50%) with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease. |
| Assessment Process | |
| Rapid review commissioned | 19/12/2016 |
| Rapid review completed | 10/01/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 11/01/2017 |
| Pre-submission consultation with Applicant | 23/01/2017 |
| Full submission received from Applicant | 10/04/2017 |
| Preliminary review sent to Applicant | 04/07/2017 |
| NCPE assessment re-commenced | 02/08/2017 |
| Factual accuracy sent to Applicant | 06/10/2017 |
| NCPE assessment re-commenced | 11/10/2017 |
| NCPE assessment completed | 13/10/2017 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations April 2018.
